Brandon Eilertson, MD

Director, Outpatient Infectious Diseases Clinic

Education and Training

Position held:

  • Assistant Professor, Location (SUNY Downstate, Downstate Medical Center, Dates (2014-present)


  • Infectious Disease, Vanderbilt University, 2010-2014


  • Internal Medicine, Emory University, 2007-2010

Medical School:

  • Case Western Reserve University, 2003-2007

Career / Research Interests

I divide my time at SUNY between patient care in the outpatient infectious diseases clinic and on the inpatient infectious diseases consult service with research on antibiotic resistance and molecular evolution in Enterobacteriaceae, particularly Klebsiella pneumoniae. Currently, I am pursuing three retrospective projects utilizing banked Klebsiella pneumoniae isolates. These projects focus on more than 6000 frozen isolates from the period 1997-2013. This includes investigating the genetic origin of successful epidemic clones using the oldest known carbapenem resistant Klebsiella pneumoniae isolates to identify the genetic backgrounds and the plasmids found in these isolates. In another project, I am performing a historical study on 571 bloodstream Klebsiella pneumoniae isolates to identify trends over time in the development of new molecular strain types and population structure as well as co-transmission of other antibiotic resistance plasmids and the frequency of porin mutations. For the last retrospective project the focus is on the current epidemic clone ST-258. This strain is associated with carbapenem resistance conferred by the KPC carbapenemase, utilizing Illumina and PacBio sequencing, I am investigating the molecular evolution of early strains to identify specific factors that resulted in KPC plasmids associating with ST-258 genetic background bacteria. Prospectively, I have established a formal network to collect resistant Enterobacteriaceae isolates at select Brooklyn hospitals. Building on the prior work of Drs. Landman and Quale, the goal of the network will be to collect carbapenem resistant bacteria on a continuous basis to identify patient risk factors and potential interventions in the borough.

  • Eilertson B, Maruri F, Blackman A, Herrera M, Samuels DC, Sterling TR. "High proportion of heteroresistance in gyrA and gyrB in fluoroquinolone resistant Mycobacterium tuberculosis clinical isolates."Antimicrobial Agents Chemotherapy. 2014.
  • Eilertson B, Maruri F, Blackman A, Guo Y, Herrera M, Shaffer C, Shyr Y, Sterling TR. "First Report of Mutation in a Drug Efflux Pump Gene Associated with Fluoroquinolone Resistance in Mycobacterium tuberculosis." J Antimicrobial Chemotherapy. In Revision.
  • Eilertson B, Del Rio C. "Purple urine bag syndrome." J Hosp Med 2008 Sept/Oct; 3(5):430.
  • Myers AJ, Eilertson B, Fulton SA, Flynn JL, Canaday DH. "The purinergic P2X7 receptor is not required for control of pulmonary Mycobacterium tuberculosis infection." Infect Immun. 2005 May;73(5):3192-5.
  • Canaday DH, Gehring A, Leonard EG, Eilertson B, Schreiber JR, Harding CV, Boom WH. "T-cell hybridomas from HLA-transgenic mice as tools for analysis of human antigen processing." J Immunol Methods. 2003 Oct 1; 281(1-2):129-42.